Tamoxifen and its new derivatives in cancer research

Claudia Rivera-Guevara1, Javier Camacho

  • 1Department of Pharmacology, Centro de Investigación y de Estudios Avanzados, Avenida Instituto Politécnico Nacional 2508, México D. F. 07360, México.

Insights

Tamoxifen, a breast cancer drug, shows anti-tumor effects beyond estrogen receptors (ER). Its non-specificity may reveal new targets for developing more potent and selective cancer therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Discovery

Background:

  • Tamoxifen is a cornerstone in breast cancer treatment and prevention for over 30 years.
  • While primarily targeting estrogen receptors (ER), tamoxifen exhibits anti-tumor activity in ER-negative cancers, indicating additional mechanisms.
  • Tamoxifen's known side effects stem from its interactions with multiple cellular pathways and ion channels.

Purpose of the Study:

  • To review current knowledge on tamoxifen and its analogues.
  • To explore recent patent literature on novel tamoxifen analogues and their therapeutic applications.
  • To elucidate the biological effects and therapeutic targets of new patented tamoxifen derivatives.

Main Methods:

  • Literature review of tamoxifen's general aspects.
  • Analysis of recent patents detailing tamoxifen analogues.
  • Description of biological effects and therapeutic targets of novel analogues.

Main Results:

  • Tamoxifen interacts with various cellular targets beyond estrogen receptors.
  • Recent patents reveal new tamoxifen analogues with distinct biological activities.
  • These analogues offer potential for targeted cancer therapy with improved specificity.

Conclusions:

  • Tamoxifen's non-specific action provides opportunities to discover new anti-cancer targets.
  • Novel tamoxifen analogues are emerging with potential for enhanced efficacy and reduced side effects.
  • This research offers a new perspective on tamoxifen-based chemotherapy for cancer patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...